Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

Eli Lilly and Co. is shelling out $1 billion to buy a Boston biotech known for genetic medicines for cardiovascular disease.

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.

Major global pharmaceutical companies traded lower in the premarket on Tuesday after President Donald Trump reiterated his ...

Chronic low back pain (CLBP) is a widespread and long-lasting condition defined by lower back pain that lasts for at least 12 weeks. The l ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CCM Investment Advisers gave Vertex Pharmaceuticals a vitamin shot by upping its stake 24.1% in Q1. They purchased an ...

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an ...

Buy-and-hold investing is a time-tested strategy that rewards patience and discipline. By owning high-quality stocks for at ...

UT Health San Antonio is the first hospital in Texas to offer patients a new, non-opioid drug as a “first-line treatment for ...